Bromovinyldeoxyuridine: Drug Facts & Uses

Introduction to Bromovinyldeoxyuridine (BVDU)

Bromovinyldeoxyuridine, also known as brivudine or BVdU, is a synthetic nucleoside analog and antiviral medication used to treat viral infections such as herpes zoster (shingles) and herpes simplex virus type 1 (HSV-1). As a thymidine analogue and uridine derivative, bromovinyldeoxyuridine exhibits selective activity against certain viruses.

Chemical Properties

The chemical name for bromovinyldeoxyuridine is ε-5-(2-Bromovinyl)-2′-deoxyuridine. Its molecular formula is C ₁₁H ₁₃BrN ₂O ₅, with a molecular weight of 333.14 g/mol. The CAS number for bromovinyldeoxyuridine is 69304-47-8, and its InChI Key is ODZBBRURCPAEIQ-PIXDULNESA-N. Bromovinyldeoxyuridine is typically available in high purity, such as ≥ 99% by HPLC [1].

arm“>Ph armacological Information

Bromovinyldeoxyuridine acts as a selective inhibitor of viral DNA synthesis. As a nucleoside analog, it is incorporated into viral DNA, leading to chain termination and inhibition of viral replication. In addition to its direct antiviral effects, bromovinyldeoxyuridine has shown pro-apoptotic and chemosensitizing properties in various studies [2].

Medical Applications

Bromovinyldeoxyuridine is primarily used for the treatment of acute herpes zoster (shingles) in immunocompetent adults. It has also been used topically for the treatment of herpes simplex virus type 1 (HSV-1) infections, such as herpes simplex keratitis. However, bromovinyldeoxyuridine is ineffective against herpes simplex virus type 2 (HSV-2) [3].

Treatment of Acute Herpes Zoster

Bromovinyldeoxyuridine is an effective anti-herpes agent for the treatment of acute herpes zoster (shingles) in immunocompetent adults. Its selective activity against varicella-zoster virus (VZV) makes it a valuable therapeutic option for this condition.

Treatment of Herpes Simplex Virus Type 1

When applied topically, bromovinyldeoxyuridine has shown efficacy in the treatment of herpes simplex virus type 1 (HSV-1) infections, such as herpes simplex keratitis. However, it is ineffective against herpes simplex virus type 2 (HSV-2).

Comparison with Idoxuridine for Herpes Simplex Keratitis

Bromovinyldeoxyuridine has been compared with idoxuridine for the treatment of herpes simplex keratitis. While both drugs are effective, bromovinyldeoxyuridine may offer advantages in terms of selectivity and potency.

Clinical Studies and Efficacy

Several clinical studies have investigated the efficacy of bromovinyldeoxyuridine against various herpesviruses:

Efficacy Against Herpes Simplex Virus Type 1 (HSV-1)

In a randomized, double-blind, multicenter trial, bromovinyldeoxyuridine demonstrated significant efficacy in the treatment of herpes simplex keratitis caused by HSV-1. The study found that bromovinyldeoxyuridine was well-tolerated and provided rapid symptom relief [4].

Efficacy Against Varicella-Zoster Virus (VZV)

A double-blind, randomized, placebo-controlled trial evaluated the efficacy of oral bromovinyldeoxyuridine in the treatment of acute herpes zoster in immunocompetent adults. The study concluded that bromovinyldeoxyuridine significantly reduced the duration and severity of zoster-associated pain and accelerated rash healing [5].

Comparative Studies with Acyclovir

Comparative studies have been conducted to assess the efficacy of bromovinyldeoxyuridine against other antiviral agents, such as acyclovir. In a randomized, double-blind study, bromovinyldeoxyuridine demonstrated non-inferiority to acyclovir in the treatment of herpes zoster in immunocompetent patients [6].

Administration and Dosage

Bromovinyldeoxyuridine is available in oral and topical dosage forms. The recommended dosage for the treatment of acute herpes zoster is 125mg once daily for 7 days. For topical application in the treatment of herpes simplex keratitis, the dosage may vary depending on the specific product used.

armacokinetics/”>Ph armacokinetics

After oral administration, bromovinyldeoxyuridine is rapidly absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism in the liver, resulting in the formation of active metabolites. The drug is widely distributed throughout the body and crosses the blood-brain barrier. Elimination occurs primarily through renal excretion of metabolites [3].

Side Effects and Safety Profile

Bromovinyldeoxyuridine is generally well-tolerated, with a favorable safety profile. Common side effects may include nausea, vomiting, diarrhea, and headache. Rarely, more serious adverse reactions, such as hepatotoxicity or hematologic abnormalities, have been reported. Bromovinyldeoxyuridine is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution should be exercised when using bromovinyldeoxyuridine in immunocompromised patients, as the drug’s safety in this population has not been fully established [3].

Synthesis and Manufacturing

Bromovinyldeoxyuridine can be synthesized through various chemical pathways, typically starting from uridine or deoxyuridine precursors. The key step involves the introduction of a bromovinyl group at the 5-position of the uridine ring. Commercial production of bromovinyldeoxyuridine often employs proprietary manufacturing processes to ensure high purity and consistency, such as ≥ 99% by HPLC [1].

Comparison with Other Antiviral Agents

Bromovinyldeoxyuridine has been compared with other antiviral agents, particularly acyclovir, in terms of efficacy, safety, and selectivity. While both drugs are effective against herpesviruses, bromovinyldeoxyuridine may offer advantages in certain clinical scenarios due to its specific mechanism of action and selective activity against VZV and HSV-1.

Legal and Regulatory Status

Bromovinyldeoxyuridine has been approved by regulatory agencies, such as the FDA and EMA, for the treatment of acute herpes zoster in immunocompetent adults. The drug’s approval dates and historical milestones vary by region and specific indication.

Commercial Availability

Bromovinyldeoxyuridine is commercially available under various brand names and trade names, depending on the country and manufacturer. It is supplied by several ph armaceutical companies worldwide.

Advanced Research Topics

Ongoing research efforts aim to further elucidate the therapeutic potential of bromovinyldeoxyuridine and explore its utility in various clinical settings. Some areas of active investigation include:

• Ongoing clinical trials evaluating bromovinyldeoxyuridine for the treatment of other viral infections
• Potential future applications of bromovinyldeoxyuridine in combination therapies or as a chemosensitizing agent
• Research on the pro-apoptotic and chemosensitizing properties of bromovinyldeoxyuridine and their implications for cancer treatment

Mechanisms of Resistance

Like other antiviral agents, the efficacy of bromovinyldeoxyuridine can be compromised by the emergence of drug-resistant viral strains. Known mechanisms of resistance include mutations in viral thymidine kinase or DNA polymerase genes, which can reduce the drug’s ability to inhibit viral replication. Strategies to overcome resistance, such as combination therapy or the development of novel antiviral compounds, are areas of ongoing research [7].

Miscellaneous

In addition to its primary use in treating herpesvirus infections, bromovinyldeoxyuridine has been investigated for other potential applications. For example, some studies have explored the use of bromovinyldeoxyuridine as part of combination therapy for the treatment of metastatic colorectal cancer, leveraging its chemosensitizing properties [2].

In conclusion, bromovinyldeoxyuridine is a valuable antiviral medication with selective activity against herpesviruses such as VZV and HSV-1. Its efficacy, safety, and unique properties make it an important therapeutic option for the management of acute herpes zoster and other viral infections. Ongoing research continues to explore the full potential of this versatile drug, both in antiviral therapy and beyond.